Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

AstraZeneca's Baxdrostat Shows Promise in Phase 3 Hypertension Trial

AstraZeneca's Baxdrostat Shows Promise in Phase 3 Hypertension Trial

AstraZeneca's aldosterone synthase inhibitor baxdrostat has demonstrated significant efficacy in reducing blood pressure among patients with treatment-resistant hypertension, according to data presented at the American Heart Association 2025 Scientific Sessions. The phase 3 Bax24 trial results mark a crucial milestone for the pharmaceutical giant's $1.3 billion investment in CinCor Pharma, the original developer of baxdrostat.

NoahAI News11/10/2025
FDA Puts Clinical Hold on Tenaya Therapeutics' Heart Disease Gene Therapy Trial

FDA Puts Clinical Hold on Tenaya Therapeutics' Heart Disease Gene Therapy Trial

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Tenaya Therapeutics' gene therapy study for MYBPC3-associated hypertrophic cardiomyopathy. The hold comes as the biotech company works to standardize immunosuppression regimens across trial sites for its TN-201 therapy.

NoahAI News11/10/2025
Hair Loss Treatments: The Next Frontier in Pharmaceutical Innovation

Hair Loss Treatments: The Next Frontier in Pharmaceutical Innovation

The pharmaceutical industry is witnessing a surge of interest in hair loss treatments, with several companies vying to develop the next blockbuster drug in this lucrative market. Recent developments suggest that hair loss could become as significant a focus for drug developers as weight loss has been in recent years, with potential for both clinical impact and commercial success.

NoahAI News11/10/2025
Eli Lilly Inks $1.2B Deal with Sanegene for Metabolic RNA Therapeutics

Eli Lilly Inks $1.2B Deal with Sanegene for Metabolic RNA Therapeutics

Eli Lilly has entered into a significant research collaboration with SanegeneBio, potentially worth up to $1.2 billion, to advance the development of cardiometabolic RNAi medicines. The partnership, announced on November 8, 2025, aims to leverage Sanegene's innovative Ligand and Enhancer Assisted Delivery (LEAD) platform to enhance the tissue-specific targeting of RNA therapeutics.

NoahAI News11/10/2025
FDA Approves J&J's Darzalex for Smoldering Multiple Myeloma, Marking Industry First

FDA Approves J&J's Darzalex for Smoldering Multiple Myeloma, Marking Industry First

In a groundbreaking development for the pharmaceutical industry, Johnson & Johnson's Darzalex Faspro has received FDA approval for the treatment of high-risk smoldering multiple myeloma (SMM), becoming the first therapy approved for this indication. This expansion of Darzalex Faspro's label represents a significant shift in the management of multiple myeloma, allowing for earlier intervention in the disease progression.

NoahAI News11/7/2025
The GLP-1 Paradox: Addressing Side Effects in the Booming Obesity Drug Market

The GLP-1 Paradox: Addressing Side Effects in the Booming Obesity Drug Market

The pharmaceutical industry is witnessing a revolution in obesity treatment with the rise of glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, have shown remarkable efficacy in weight loss. However, a significant challenge threatens to undermine their potential: severe gastrointestinal side effects leading to high discontinuation rates.

NoahAI News11/7/2025
Patient Death in Intellia's CRISPR Trial Halts Phase 3 Studies

Patient Death in Intellia's CRISPR Trial Halts Phase 3 Studies

Intellia Therapeutics faces a significant setback as a patient death in its phase 3 clinical trial for the CRISPR-based therapy nex-z leads to a halt in dosing. The incident raises concerns about the therapy's safety profile and potential market impact.

NoahAI News11/7/2025
FDA Awards Second Round of Commissioner's National Priority Vouchers to Major Biopharma Companies

FDA Awards Second Round of Commissioner's National Priority Vouchers to Major Biopharma Companies

The U.S. Food and Drug Administration (FDA) has announced the recipients of its second batch of Commissioner's National Priority (CNP) vouchers, awarding six to larger biopharma companies for drugs that are mostly already on the market. This move marks a shift from the first round of recipients, which included a mix of large and small pharmas at various stages of drug development.

NoahAI News11/7/2025
Moderna's Financial Struggles Continue, but Cost-Cutting Measures Show Promise

Moderna's Financial Struggles Continue, but Cost-Cutting Measures Show Promise

Moderna, the mRNA vaccine manufacturer, reported its fourth consecutive quarter of losses but is showing signs of financial improvement through aggressive cost-cutting measures. The company's third-quarter earnings call revealed a net loss of $200 million, a significant reduction from the $1 billion loss in the first quarter and $800 million in the second quarter of 2025.

NoahAI News11/7/2025
Eli Lilly's Eloralintide Achieves 20% Weight Loss, Advancing to Phase III Trials

Eli Lilly's Eloralintide Achieves 20% Weight Loss, Advancing to Phase III Trials

Eli Lilly's amylin agonist eloralintide has demonstrated impressive efficacy in a Phase II trial, achieving up to 20.1% weight loss after 48 weeks. This breakthrough has positioned the company to begin Phase III studies in December, potentially challenging current market leaders in obesity treatment.

NoahAI News11/7/2025
Tidepool and Ōura Partner to Advance Diabetes Research with Comprehensive Biometric Data

Tidepool and Ōura Partner to Advance Diabetes Research with Comprehensive Biometric Data

In a groundbreaking collaboration announced on Tuesday, diabetes tech nonprofit Tidepool is joining forces with smart ring maker Ōura to launch a pioneering diabetes research initiative. This partnership aims to create one of the most comprehensive real-world datasets for diabetes by combining biometric data from Ōura Ring Gen 3 devices with information from continuous glucose monitors (CGMs) and insulin pumps.

NoahAI News11/7/2025
Improving Clinical Trial Compliance Through Patient-Centric Technology

Improving Clinical Trial Compliance Through Patient-Centric Technology

In a recent episode of BioSpace's podcast, industry experts discussed innovative approaches to enhance patient experience and compliance in clinical trials by leveraging thoughtful technology integration. The conversation, featuring Oliver Eden from Jabil and Travis Webb from PII, shed light on the potential of autoinjectors and smart technologies to revolutionize clinical trial processes.

NoahAI News11/7/2025
1234...67»